The recent FDA approval of a CAR-T cell based therapy has been an important milestone for progress in how we collectively can target and treat diseases. A key tool in these therapies have been Dynabeads for selection and activation of target cells. One important workflow step is the removal of Dynabeds after their use and prior to patient administration of cells.
To further improve Dynabead removal outcomes for users of the DynaMag CTS system, we have endeavored to create a bioprocess container (BPC) with improved Dynabead retention characteristics. This bag leverages existing film and manufacturing expertise from Thermo Fisher Scientific that have been extensively used in the biopharmaceutical industry over the past decade. Fundamentally, this designed-for-purpose BPC increases the flow path of fluid over the DynaMag to provide longer exposure to magnetic fields. This in turn provides for superior Dynabead removal from the fluid when compared to standard bags without this design as demonstrated in Figure 1.
Please click Additional Files below to see the full abstract
